Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claus Garbe

Showing results (221-230 of 501) with videos related to

Pageof 51
Sort By:
Neuro-Oncology Advances|December 11, 2020
An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER studyTeresa Amaral, Heike Niessner, Tobias Sinnberg, et al.
The Journal of Investigative Dermatology|March 8, 2008
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cellsKonstantinos G Lasithiotakis, Tobias W Sinnberg, Birgit Schittek, et al.
European Journal of Cancer (Oxford, England : 1990)|July 11, 2017
Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysisNatalie J Ives, Stefan Suciu, Alexander M M Eggermont, et al.
Journal of the American Academy of Dermatology|April 25, 2009
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patientsFriedegund Meier, Emmanuella Guenova, Stephan Clasen, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 19, 2011
Melanocytic neviAxel Hauschild, Friederike Egberts, Claus Garbe, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2021
Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036Claus Garbe, Ulrike Keim, Sara Gandini, et al.
Cancer Immunology, Immunotherapy : CII|December 22, 2010
Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-upBenjamin Weide, Thomas Kurt Eigentler, Annette Pflugfelder, et al.
The Journal of Investigative Dermatology|October 6, 2016
High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV MelanomaBenjamin Weide, Tina Schäfer, Alexander Martens, et al.
Plos One|December 7, 2013
Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapyBenjamin Weide, Sabina Richter, Petra Büttner, et al.
Molecular Cancer|February 19, 2018
Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotypeTobias Sinnberg, Mitchell P Levesque, Jelena Krochmann, et al.
Pageof 51

Showing results (221-230 of 501) with videos related to

Sort By:
Pageof 51
Neuro-Oncology Advances|December 11, 2020
An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER studyTeresa Amaral, Heike Niessner, Tobias Sinnberg, et al.
The Journal of Investigative Dermatology|March 8, 2008
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cellsKonstantinos G Lasithiotakis, Tobias W Sinnberg, Birgit Schittek, et al.
European Journal of Cancer (Oxford, England : 1990)|July 11, 2017
Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysisNatalie J Ives, Stefan Suciu, Alexander M M Eggermont, et al.
Journal of the American Academy of Dermatology|April 25, 2009
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patientsFriedegund Meier, Emmanuella Guenova, Stephan Clasen, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 19, 2011
Melanocytic neviAxel Hauschild, Friederike Egberts, Claus Garbe, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2021
Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036Claus Garbe, Ulrike Keim, Sara Gandini, et al.
Cancer Immunology, Immunotherapy : CII|December 22, 2010
Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-upBenjamin Weide, Thomas Kurt Eigentler, Annette Pflugfelder, et al.
The Journal of Investigative Dermatology|October 6, 2016
High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV MelanomaBenjamin Weide, Tina Schäfer, Alexander Martens, et al.
Plos One|December 7, 2013
Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapyBenjamin Weide, Sabina Richter, Petra Büttner, et al.
Molecular Cancer|February 19, 2018
Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotypeTobias Sinnberg, Mitchell P Levesque, Jelena Krochmann, et al.
Pageof 51